WE ARE
A pharmaceutical company specialized in high quality
ONCOLOGY PRODUCTS
We are a pharmaceutical company specialized in high-quality oncology products in the Middle East. Actero is the result of the joint venture between Actoverco (the Iranian leading pharmaceutical company) and a renowned multinational company currently present in 120 countries.
January 23, 2024

Production of two new blood pressure medicines in the country

January 23, 2024

Merck, Actover’s reliable partner in the transfer of the most advanced pharmaceutical technologies to Iran

June 26, 2023

EHA 2023 Actero Sponsorship

July 24, 2022

Actero Support in Congress 1400

November 16, 2021

Best of ASCO 2021

November 16, 2021

“Uro-Oncology Tumor board: Challenges of Prostate Cancer Treatment” (Semi-Virtual)

December 20, 2020

Lung Cancer & COVID-19 Webinar.

December 20, 2020

“Updates on Colorectal Cancer” Webinar

October 20, 2020

Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.

October 20, 2020

Breast Cancer Webinar

We are building a unique range of products to cover the needs of cancer patients. Actero is not only focused on chemotherapy, but understands cancer treatment as a whole. That is why we invest in high-quality oncology drugs, as well as in palliative care. All across our portfolio, every Actero medicine stands for reliability.

January 23, 2024

Production of two new blood pressure medicines in the country

Specialists at a pharmaceutical company have developed two new drugs to treat high blood pressure, a condition that affects approximately 32 million Iranians to varying degrees. The CEO of Actoverco pharmaceutical group, Reza Karimi Mostofi, reported that the specialists of his group have successfully provided the blood pressure medication Telmic-H to patients in Iran. Telmic-H is the first medication of its kind in Iran, containing telmisartan/hydrochlorothiazide. This medication comes in the form of coated tablets in two strengths: 80/12.5 and 80/25 mg. It is commonly used to treat high blood pressure. He stated that approximately 32 million people in Iran suffer from high blood pressure, which is one of the leading causes of cardiovascular diseases, including heart attacks, strokes, and fatalities resulting from these conditions.Cardiovascular accidents tend to occur more frequently in the early morning hours when the balance of certain hormones in the body is disrupted. Telmisartan/hydrochlorothiazide Actoverco medicine has several benefits, including constant monitoring of blood pressure, especially during sleep at night and in the early morning, which helps in maintaining a healthy blood pressure level. Mostofi stated that taking this medication can regulate blood pressure for 24 hours and minimize side effects. He mentioned that the company has introduced another new medicine named Irbesal (Irbesartan) at the Salamat Bonyan exhibition of science-based products in the field of food, medicine, and medical equipment. Irbesal is available in the form of coated and lined tablets of 300mg. Actoverco’s CEO stated that this drug is used to treat high blood pressure and diabetic nephropathy. He pointed out that high blood pressure, which unfortunately is quite prevalent in the country, is one of the leading causes of cardiovascular and kidney diseases. He affirmed that high blood pressure complications in diabetic patients, with uncontrolled high blood sugar, can cause damage to the kidney vessels and cells. This damage to cells will eventually lead to kidney failure.In addition to controlling blood pressure, Irbesartan can be effective in preventing diabetic nephropathy, which is the excretion of protein from the kidneys. The CEO of Actoverco Pharmaceuticals has stated that their company produces almost 400 different pharmaceutical products across 15 therapeutic areas. These products range from general disease treatments to high-risk oncology, hormonal, and biological drugs. The pharmaceutical complex is also involved in producing raw materials and supplements. To support the development of knowledge-based activities in the healthcare field, the Actotech accelerator has been launched. Mostofi stated that the knowledge-based complex became operational in 2020. The complex was inaugurated by the president’s scientific and technological deputy and the secretary of the biotechnology development staff. Currently, it is an advanced research and development complex that fulfills the requirements of a science and technology park. It supports the commercialization of innovative ideas across various fields, such as biotechnology drugs, vaccines, new drug formulations, personalized medicine, smart health, diagnostic kits, food quality control, as well as the field of raw materials, and factory production line equipment.
/
January 23, 2024

Merck, Actover’s reliable partner in the transfer of the most advanced pharmaceutical technologies to Iran

Merck, a German company, is one of the oldest manufacturers of drugs, chemicals, and health materials globally, and it is a leading name in the research and development (R&D) field in these sectors. The company exports its products to over 60 countries worldwide and is renowned for its innovative technology in the pharmaceutical industry. Merck’s production groups manufacture over 20,000 specialized pharmaceuticals, laboratory products, and special chemicals across various sectors. This company has started its activity in the field of trading and selling drugs in Iran since 1968. Actover Pharmaceutical Company has been successfully present in the Iranian pharmaceutical market for over half a century. They have achieved this with the help of the highest standards and the most advanced technologies and equipment in the world. As a result, they have gained the attention of major foreign companies, including Merck. Actovar is a company committed to producing high-quality pharmaceutical products using the latest technology, expert personnel, and smart selection of new products. It is proud to have obtained the highest quality standards and approvals, making it a capable partner of Merck in Iran and the surrounding region. It’s partnership allows it to produce drugs for this large German company and provide easy and affordable access to the latest pharmaceutical innovations from Merck
/
June 26, 2023

EHA 2023 Actero Sponsorship

/
Find Your Product
With our products, we contribute to the health of people and plants. Here you find an overview of the major Acteropharma products.
A
Z
We understand that pharmaceutical industry is not comparable to other industries. That is why ethical behavior is at the heart of our business.